Advertisement

Topics

Glenmark’s Phase IIa study of atopic dermatitis drug shows improved symptoms

19:00 EDT 31 Jul 2017 | Net Resources International

Glenmark Pharmaceuticals has reported positive results from the Phase IIa clinical trial of its investigational candidate GBR 830 in patients with atopic dermatitis.

Original Article: Glenmark’s Phase IIa study of atopic dermatitis drug shows improved symptoms

NEXT ARTICLE

More From BioPortfolio on "Glenmark’s Phase IIa study of atopic dermatitis drug shows improved symptoms"

Quick Search
Advertisement
 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...